Search
JPC-3210
go.drugbank.com/drugs/DB15609ExperimentalJPC-3210 is a potent antimalarial agent. … , and favourable preclinical pharmacokinetics including a lengthy plasma elimination half-life.
CK0802
go.drugbank.com/drugs/DB15866InvestigationalCK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching.
XP21279
go.drugbank.com/drugs/DB06319InvestigationalXP21279 is a prodrug of [Levodopa], a dopamine precursor used in the management of Parkinson's disease. … XP21279 was under investigation in clinical trial NCT00914602 (An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects), administered in combination with [Carbidopa
SQ-109
go.drugbank.com/drugs/DB05186InvestigationalSQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB.
(S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole
go.drugbank.com/drugs/DB08725ExperimentalThese are aromatic compounds containing an ether group substituted with a benzene ring. This substance targets the protein genome polyprotein. … (S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole is a solid. This compound belongs to the phenol ethers.
Pimagedine
go.drugbank.com/drugs/DB05383InvestigationalIt is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies.
Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.
CTx-PDE6b
go.drugbank.com/drugs/DB17858InvestigationalCTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.
Human ciliary neurotrophic factor, recombinant (E. coli)
go.drugbank.com/drugs/DB17959ExperimentalThe trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia
VY-HTT01
go.drugbank.com/drugs/DB16999InvestigationalVY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA. … VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression.